Lipella Pharmaceuticals INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
OTC.Pink
Form 4: Lipella Pharmaceuticals Insider Filing: Jonathan Kaufman Reports Changes in Beneficial Ownership
Jonathan Kaufman, a director, 10% owner, and officer of Lipella Pharmaceuticals, reported changes in beneficial ownership related to convertible preferred stock and warrants following the effectiveness of a registration statement.
OTC.Pink
Lipella Pharmaceuticals' CEO, Jonathan Kaufman, secures voting power over shares held by Spartan Capital Securities and its affiliates via an irrevocable proxy agreement.
OTC.Pink
Lipella Pharmaceuticals' CEO, Jonathan Kaufman, secures voting control over shares held by Spartan Capital Securities and its affiliates via an irrevocable proxy agreement.
OTC.Pink
Form 4: Lipella Pharmaceuticals CEO Gains Voting Power Over Spartan Capital's Shares via Irrevocable Proxy
Lipella Pharmaceuticals' CEO, Jonathan Kaufman, secures voting control over shares held by Spartan Capital Securities and its affiliates through an irrevocable proxy agreement.
OTC.Pink
Form 4: Lipella Pharmaceuticals Executive Reports Changes in Beneficial Ownership Following Registration
Jonathan H. Kaufman, a director and officer of Lipella Pharmaceuticals, reported changes in his beneficial ownership of company securities following the effectiveness of a registration statement.
OTC.Pink
Form 4: Lipella Pharmaceuticals Grants Irrevocable Proxy to CEO for Spartan Capital Securities Shares
Lipella Pharmaceuticals has granted its CEO, Jonathan Kaufman, an irrevocable proxy to vote shares held by Spartan Capital Securities, related to consulting and placement agent agreements.
OTC.Pink
Form 4: Lipella Pharmaceuticals Grants Irrevocable Proxy to CEO for Spartan Capital Securities Shares
Lipella Pharmaceuticals has granted its CEO, Jonathan Kaufman, an irrevocable proxy to vote shares held by Spartan Capital Securities, related to a consulting and placement agent agreement.
OTC.Pink
Director Jonathan H. Kaufman of Lipella Pharmaceuticals Inc. (LIPO) purchased 10,000 shares of common stock at an average price of $0.759 on May 14, 2024, increasing his total holdings.
OTC.Pink
Ryan Pruchnic, a director of LiPella Pharmaceuticals, acquired 25,000 stock options on March 15, 2024.
OTC.Pink
Director Naoki Yoshimura reports acquisition of 25,000 stock options in LIPELLA PHARMACEUTICALS INC. on March 15, 2024.
OTC.Pink
Michael B. Chancellor, Chief Medical Officer and Director of LiPella Pharmaceuticals, reports the acquisition of 80,000 stock options.
OTC.Pink
Director Lori Birder reports acquiring 25,000 stock options in Lipella Pharmaceuticals on March 15, 2024.
OTC.Pink
Jonathan H. Kaufman, a director, 10% owner, and officer of LiPella Pharmaceuticals, recently purchased additional shares of the company's common stock on the open market.
OTC.Pink
Douglas Johnston, CFO of LiPella Pharmaceuticals, reports the acquisition of 50,000 stock options on March 15, 2024.
OTC.Pink
Daniel R. Cohen, a director of LiPella Pharmaceuticals, acquired 25,000 stock options on March 15, 2024.
OTC.Pink
Byong Kim, a director of Lipella Pharmaceuticals, acquired 25,000 stock options on March 15, 2024.
OTC.Pink
Jonathan H. Kaufman, a director at Lipella Pharmaceuticals, acquired 144,906 shares of common stock at a price of $0.6901 per share on March 13, 2024.
OTC.Pink
Michael B. Chancellor, a director and Chief Medical Officer of LiPella Pharmaceuticals, acquired 144,906 shares of common stock at $0.6901 per share on March 13, 2024.